Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?

"Humana's surge reflects a stack of catalysts centered on Medicare Advantage (MA). A favorable MA rate decision earlier this year lifted a major regulatory overhang, and Humana's concentrated MA exposure means it benefits more than diversified peers. Bernstein recently raised its price target on the stock to $288 from $211, citing improved MA final rates and positive Q1 utilization signals."

"Humana's Q1 2026 results reinforced the recovery narrative. Humana's adjusted EPS of $10.31 beat the $10.20 consensus, while revenue rose 24% year over year (YoY) to $39.65 billion. The insurance segment benefit ratio of 89% landed favorable to internal guidance."

"Management affirmed FY2026 adjusted EPS guidance of at least $9 and revenue of at least $160 billion. Humana CEO Jim Rechtin stated the company has had "a solid start to the year" and feels good about how operating execution is setting Humana up for the future. Individual MA membership is up 22% year to date (YTD)."

"That run has put Humana well ahead of UnitedHealth Group ( NYSE:UNH), up 19% over the same stretch, and Cigna Group ( NYSE:CI), up just 2.5%. The performance gap is striking for three companies that occupy overlapping corners of the same industry. So is Humana genuinely outperforming, or just snapping back from a deep multi-year drawdown? The short answer is yes, HUM stock is leading the pack by a meaningful margin."

Humana shares trade near $303 after a slightly lower midday move following a flat open. Over the past month, the stock rises 48%, outperforming UnitedHealth Group at 19% and Cigna Group at 2.5% despite overlapping managed care exposure. The rally is attributed to Medicare Advantage catalysts, including a favorable rate decision that reduced a regulatory overhang and improved final rates. Humana’s concentrated Medicare Advantage exposure amplifies the impact versus more diversified peers. Q1 2026 results show adjusted EPS of $10.31 beating consensus and revenue up 24% year over year to $39.65 billion. The insurance benefit ratio of 89% met favorable guidance, and management reaffirmed FY2026 adjusted EPS and revenue targets. Individual MA membership is up 22% year to date.

Read at 24/7 Wall St.